Pro-apoptotic Bcl-2 family member Bax is a crucial protein in the induction of apoptosis and its activation is required for this process. Here we report that Bax is a short-lived protein in malignant B-cells and Bax protein levels decreased rapidly when protein synthesis was blocked. 
Introduction
Bax is a critical element in the induction of apoptosis and having adequate levels of intracellular Bax protein are crucial for cells to die by apoptosis in response to death signals. During the apoptotic process, Bax translocates from the cytosol to the mitochondria and undergoes conformational changes. Insertion into the mitochondrial membrane is essential for the proapoptotic activity of Bax. However, Bax protein has a shortened half-life in cancer cells due to greatly increased proteasome-dependent degradation activity.
1 Low levels of, or absent, Bax protein in malignant cells are associated with significant resistance to cancer therapy. Instability of Bax has been found in several types of malignant cells, including Jurkat T-cell and pre-B acute lymphoblastic leukemia 697 cell lines, 2 primary chronic lymphocytic leukemic cells (CLL), 3 cervical cancer Hela cell line, 4 and advanced human prostate cancer. 1 Decrease of Bax protein was significantly correlated with a poor prognosis in prostate cancer 1 and primary superficial-spreading melanoma.
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DNA damaging agents via p53-dependent and p53-independent pathways.
13,16
Proteasome inhibitors also have the ability to increase or maintain Bax protein levels -which are critical for Bax activation -when used alone or in combination with other agents. 17-20 TNF-related apoptosis inducing ligand (TRAIL) is a promising anti-cancer agent. However, malignant Bcells are resistant to TRAIL-induced apoptosis. 21, 22 We have previously found that Bax protein levels decline in leukemic cell lines during treatment with TRAIL. 23 It is unclear whether this could be one of the mechanisms of the resistance of malignant B-cells to TRAIL.
Bortezomib (PS-341, Velcade®) is a novel, first-in-class proteasome inhibitor with antitumor activity against a number of hematological and non-hematological malignancies. 24 In vitro studies showed that Bortezomib selectively inhibits proteasome-dependent degradation of p53, 25 IκB, 26 p21, 27 Noxa, 9, 28 and TRAIL receptors DR4 and DR5. 29 Proteasome inhibitors have been shown to be a promising approach for overcoming the resistance of tumor cells to TRAILinduced apoptosis.
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Overexpression of Bcl-2 is one of the characteristics of malignant B-cells. However, the role of Bax on malignant B-cell survival and resistance to therapy has not been widely studied.
This study has looked at Bax protein instability in malignant B-cells and the critical role of Bortezomib in the induction of Bax activation. 
Materials and Methods

Materials
Apoptosis assays by flow cytometry
Apoptosis was determined by both Annexin V and DNA content assays. The Annexin V assay was performed according to the protocol of the Annexin V-FITC kit. Whole cells in the binding buffer suspension were stained with 5 μl of Annexin V-FITC and 10 μl of propidium iodide (PI)
for 15 minutes at the room temperature in the dark. Annexin V-FITC and PI fluorescence were measured on the FL1-H and FL3-H channels, respectively, by flow cytometry (Becton Dickinson FACScan). Annexin V positive cells (both PI negative and positive) were defined as apoptotic. DNA content was measured by flow cytometry as described previously.
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Preparation of cellular fractions
Cells (5 ×10 7 ) were washed in Ca μmol/L cytochalasin B) and incubated for 20 minutes on ice. Cells were then broken with a glass Dounce homogenizer. Nuclei were separated by spinning at 790 ×g for 10 minutes at 4°C.
The post-nuclear supernatant was further spun at 10,000 ×g for 10 minutes at 4°C to separate cytosol and mitochondria. The crude mitochondrial pellet was purified by passing through a sucrose gradient (100-300 mmol/L) cushion at 9,000 ×g for 8 minutes. 
RT-PCR
Total RNA was extracted with the RNeasy mini kit. 1 to 5 µg RNA was used for reverse transcription. cDNA was synthesized with the first-strand synthesis kit and amplified with Bax primers (5'CCCTTTTGCTTCAGGGTTTC, and 3' primer TGTTACTGTCCAGTTCGTCC size 151bp) or actin primers (5' GGAACGGTGAAGGTGACAG and 3' primer GGGACAA AAAGGGGGAAG size 338bp). PCR program was set up as below: cDNA templates denatured at 94°C for 2 minutes, followed by 30 cycles of denaturation at 94°C for 15 seconds, annealing at 56°C for 20 seconds, and an extension at 72°C for 20 seconds. Additional extension was at 72°C for 10 minutes. The PCR product was detected in 2% agarose gel.
Results
Bax is a short-lived protein in malignant B-cell lines
The expression of the Bcl-2 family of proteins was determined in the malignant B-cell lines, 
TRAIL induces Bax degradation in malignant B-cell lines
The malignant B-cells with low Bax protein expression, CRL and DoHH2, were found to be more resistant to TRAIL-induced apoptosis compared with the HRC cell line. DHL-4 cells, which had no detectable Bax protein, were highly resistant to TRAIL (Figure 2 These results further confirmed that the down-regulation of Bax in malignant B-cells is regulated at the post-translational level. Bax degradation contributes to resistance of malignant B-cells to TRAIL-induced apoptosis, which can be reversed by proteasome inhibition leading to stabilization of Bax protein levels.
Bax degradation occurs in the mitochondrion and can be prevented by tBid or Bortezomib
To understand why TRAIL triggers Bax degradation and whether it is associated with Bax translocation to mitochondria, the location of Bax degradation was tested. Mitochondria isolated from the human leukemic K562 cell line were used as a model because they possess an inactive form of the Bax protein. 
Discussion
In 
